达比加群酯的给药剂量。（注：原文darbepoetin alfa是促红细胞生成素，这里按字面翻译了，感觉可能有误，也许应该是dabigatran etexilate，供你参考核对。） - Suppr

Suppr

超能文献

Dosing darbepoetin alfa.

作者信息

Nissenson Allen R

出版信息

Am J Kidney Dis. 2002 Oct;40(4):872. doi: 10.1053/ajkd.2002.36566.

DOI:10.1053/ajkd.2002.36566

PMID:12324929

Abstract

摘要

相似文献

Dosing darbepoetin alfa.

Am J Kidney Dis. 2002 Oct;40(4):872. doi: 10.1053/ajkd.2002.36566.

Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.

Ann Pharmacother. 2009 Feb;43(2):228-34. doi: 10.1345/aph.1K664. Epub 2009 Jan 6.

Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.

Ann Pharmacother. 2005 Nov;39(11):1808-11. doi: 10.1345/aph.1G329. Epub 2005 Sep 27.

Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).

Am J Nephrol. 2006;26(2):149-56. doi: 10.1159/000092852. Epub 2006 Apr 21.

Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data.

Nephrol Nurs J. 2005 Jul-Aug;32(4):399-407.

Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.

Pediatr Nephrol. 2002 Nov;17(11):933-7. doi: 10.1007/s00467-002-0932-0. Epub 2002 Sep 14.

The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.

Nephrol Dial Transplant. 2006 Oct;21(10):2846-50. doi: 10.1093/ndt/gfl387. Epub 2006 Aug 5.

[Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].

Nefrologia. 2003;23(2):114-24.

Epoetin alfa and darbepoetin alfa go head to head.

J Clin Oncol. 2006 May 20;24(15):2233-6. doi: 10.1200/JCO.2006.05.7794.

[Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].

Nefrologia. 2004;24(1):54-9.

引用本文的文献

Effect of erythropoiesis-stimulating agent types on malignancy in hemodialysis patients.

Clin Kidney J. 2025 Jun 16;18(6):sfaf148. doi: 10.1093/ckj/sfaf148. eCollection 2025 Jun.

Advancing Anemia Management in Chronic Kidney Disease: Assessing the Superiority of Darbepoetin Alfa Over Erythropoietin Alpha.

Cureus. 2024 Jan 3;16(1):e51613. doi: 10.7759/cureus.51613. eCollection 2024 Jan.

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.

Equivalent Doses Matter, Rather Than Types.

J Am Soc Nephrol. 2019 Sep;30(9):1772-1773. doi: 10.1681/ASN.2019060569. Epub 2019 Aug 16.

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Cochrane Database Syst Rev. 2014 Dec 8;2014(12):CD010590. doi: 10.1002/14651858.CD010590.pub2.

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability.

Int J Nephrol Renovasc Dis. 2014 Oct 9;7:353-9. doi: 10.2147/IJNRD.S61895. eCollection 2014.

Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.

Cochrane Database Syst Rev. 2014 May 28;2014(5):CD003895. doi: 10.1002/14651858.CD003895.pub3.

Darbepoetin for the anaemia of chronic kidney disease.

Cochrane Database Syst Rev. 2014 Mar 31;2014(3):CD009297. doi: 10.1002/14651858.CD009297.pub2.

Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

Drugs. 2004;64(5):499-509. doi: 10.2165/00003495-200464050-00004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验